Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes
Investigative Opthalmology & Visual Science · 2023-06-23 · 64 (7) · 35
DOI: 10.1167/iovs.64.7.35 ↗At a glance
Randomisierte kontrollierte Studie in Investigative Opthalmology & Visual Science, published on 2023-06-23. Written by Stephanie Trejo Corona and 8 co-authors. Institution: Retina Consultants of Texas, Retina Consultants of America, Houston, Texas, United States. Major MEDLINE topics: Ranibizumab, Macular Edema. Cited 6 times so far (Crossref); 25 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
Radiation retinopathy (RR)-related macular edema commonly causes poor visual acuity outcomes in patients previously treated with ocular radiation therapy. Current treatments are not US Food and Drug Administration (FDA)-approved and prior studies have variable outcomes. We performed a multicenter, prospective, randomized clinical trial to assess the safety and efficacy of 2 mg intravitreal aflibercept injections (IAIs) for the treatment of RR.
Methods
Thirty-nine eyes in 39 patients with RR-related macular edema causing vision loss were assigned randomly to cohorts (1:1 ratio) in which patients either did or did not receive a loading dose of 3 IAIs followed by a treat-and-extend regimen. The primary outcome measure was the mean Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA) change from baseline.
Results
Of the 39 randomized patients, 30 (76.9%) completed the year 1 follow-up visit. The overall mean BCVA change from baseline was 4.3 letters (P = 0.087), with 1.57 letters and 6.69 letters gained in cohorts 1 and 2, respectively (P = 0.31). There was a significant difference in central retinal thickness (CRT) from baseline to week 52 overall (484.4 µm to 326.5 µm) and within cohorts 1 (441.2 µm to 311.1 µm) and 2 (522.3 µm to 339.9 µm), respectively (P < 0.001). A total of 96.7% of the patients had visual acuity of 20/200 or better, and 30.0% improved 10 or more letters.
Conclusions
Aflibercept may improve CRT and may prevent vision loss in patients with RR using a treat-and-extend regimen through 52 weeks of therapy. Larger, multicenter studies are needed to confirm these findings.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Retina Consultants of Texas, Retina Consultants of America, Houston, Texas, United States.
- John P. and Kathrine G. McGovern Medical School at UT Health Houston, Houston, Texas, United States.
- Retina Specialists of Michigan, Grand Rapids, Michigan, United States.
- Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas, United States.
Cite
APA
Trejo Corona, S., Villanueva Boone, C., Ali, A. M., Moore, C., Brown, A., Munoz, J., Aaberg, T., Schefler, A. C., & ARRT Study Group (2023). Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes. Investigative Opthalmology & Visual Science, 64(7), 35. https://doi.org/10.1167/iovs.64.7.35
Vancouver
Trejo Corona S, Villanueva Boone C, Ali AM, Moore C, Brown A, Munoz J, et al. Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes. Investigative Opthalmology & Visual Science. 2023;64(7):35. doi:10.1167/iovs.64.7.35
BibTeX
@article{TrejoCorona2023,
author = {Trejo Corona, Stephanie and Villanueva Boone, Cecilia and Ali, Amna M and Moore, Chelsey and Brown, Alexandra and Munoz, Jose and Aaberg, Thomas and Schefler, Amy C and ARRT Study Group, ARRT Study Group},
title = {Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes},
journal = {Investigative Opthalmology & Visual Science},
year = {2023},
volume = {64},
number = {7},
pages = {35},
doi = {10.1167/iovs.64.7.35}
}
EUVIMED